[{"id":"adela-mced","name":"Adela multi-cancer methylome test","tldr":"Adela's blood test in development for 20 cancer types, built on reading DNA methylation across the whole genome; no peer-reviewed screening results yet.","route":"/drugs/adela-mced/","status":"emerging","kind":"drug","molecule":"adela-mced","modality":"Multi-cancer early detection blood test in development (genome-wide methylome enrichment)","sub":"Adela","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"afirma","name":"Afirma Genomic Sequencing Classifier","tldr":"A gene test on the needle sample from a thyroid lump that can safely call an 'uncertain' result benign and spare an operation.","route":"/drugs/afirma/","status":"established","kind":"drug","molecule":"afirma","modality":"RNA-sequencing rule-out classifier test (indeterminate thyroid nodules)","sub":"Afirma GSC","facets":{"kind":["Treatment"],"cancers":["Thyroid cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Thyroid cancer","href":"/cancers/thyroid/","tip":"Thyroid cancer is usually curable with surgery and radioactive iodine, the original theranostic. Rare aggressive forms respond to RET and BRAF inhibitors."}],"tags":[]},"sortKeys":{"year":0}},{"id":"ai-cancerch","name":"ai-CANCERCH","tldr":"GC Genome's blood test from South Korea, launched in 2023 for six cancers, built on a method published with KAIST.","route":"/drugs/ai-cancerch/","status":"emerging","kind":"drug","molecule":"ai-cancerch","modality":"Multi-cancer blood test (low-coverage whole-genome sequencing, fragmentomics)","sub":"ai-CANCERCH","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"aminoindex-cancer-screening","name":"AminoIndex Cancer Screening (AICS)","tldr":"Ajinomoto's Japanese blood test that ranks the risk of several cancers separately from amino acid levels; in a validation of 10,245 people it found 34 cancers.","route":"/drugs/aminoindex-cancer-screening/","status":"emerging","kind":"drug","molecule":"aminoindex-cancer-screening","modality":"Cancer risk blood test (plasma free amino acids), separate scores per cancer","sub":"AminoIndex","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"avantect-mcd","name":"Avantect Multi-Cancer Detection Test","tldr":"ClearNote Health's blood test for several cancers, one of the two tests in the US National Cancer Institute's randomised Vanguard study, with no published performance figures yet.","route":"/drugs/avantect-mcd/","status":"emerging","kind":"drug","molecule":"avantect-mcd","modality":"Multi-cancer early detection blood test (cell-free DNA 5-hydroxymethylcytosine)","sub":"Avantect","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"bracanalysis-cdx","name":"BRACAnalysis CDx","tldr":"The inherited BRCA test that decides who can have PARP inhibitor pills for ovarian, breast, pancreatic and prostate cancer.","route":"/drugs/bracanalysis-cdx/","status":"approved","kind":"drug","molecule":"bracanalysis-cdx","modality":"Germline BRCA1/2 sequencing companion diagnostic test","sub":"BRACAnalysis CDx","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer","HR-positive / HER2-negative breast cancer","Triple-negative breast cancer","Pancreatic ductal adenocarcinoma","Prostate cancer"],"year":["2014"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"year":{"facet":"year","value":"2014"},"tags":[]},"sortKeys":{"year":2014}},{"id":"breast-cancer-index","name":"Breast Cancer Index","tldr":"The only test designed to tell a woman who has finished five years of hormone therapy whether another five years is worth the side effects.","route":"/drugs/breast-cancer-index/","status":"established","kind":"drug","molecule":"breast-cancer-index","modality":"Gene-expression prognostic and predictive assay (extended endocrine therapy benefit)","sub":"Breast Cancer Index (BCI)","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"anpac-cda","name":"Cancer Differentiation Analysis (CDA)","tldr":"A Chinese blood test that measures physical properties of blood rather than molecules; its developer has since turned to a different business, and the test's status is unclear.","route":"/drugs/anpac-cda/","status":"emerging","kind":"drug","molecule":"anpac-cda","modality":"Cancer screening blood test (biophysical properties of blood)","sub":"CDA","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"cancerfind","name":"CancerFind","tldr":"IMBdx's blood test from South Korea, offered at screening centres there, which in a laboratory study detected nine in ten cancers including stage I.","route":"/drugs/cancerfind/","status":"emerging","kind":"drug","molecule":"cancerfind","modality":"Multi-cancer early detection blood test (whole-genome methylation sequencing with fragmentomics)","sub":"CancerFind","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"cancerseek","name":"CancerSEEK","tldr":"The Johns Hopkins blood test that first showed one draw could find several cancers and point to the organ; its approach passed to Thrive Earlier Detection and then to Exact Sciences, whose Cancerguard test followed.","route":"/drugs/cancerseek/","status":"historic","kind":"drug","molecule":"cancerseek","modality":"Multi-cancer blood test (cell-free DNA mutations and proteins), research assay","sub":"CancerSEEK","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"carcimun-test","name":"Carcimun test","tldr":"A German blood test that measures how blood proteins change shape; the only studies are small, run with the inventor, and do not say how often it finds early cancers.","route":"/drugs/carcimun-test/","status":"emerging","kind":"drug","molecule":"carcimun-test","modality":"Multi-cancer blood test (optical extinction of plasma protein conformation)","sub":"Carcimun","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"clonoseq","name":"clonoSEQ","tldr":"A DNA test that counts leftover leukaemia, myeloma or lymphoma cells down to one in a million, used to decide whether treatment has really worked.","route":"/drugs/clonoseq/","status":"approved","kind":"drug","molecule":"clonoseq","modality":"NGS minimal residual disease test (immunoglobulin and T-cell receptor clonotypes)","sub":"clonoSEQ","facets":{"kind":["Treatment"],"cancers":["Acute lymphoblastic leukaemia","Multiple myeloma","Chronic lymphocytic leukaemia","Diffuse large B-cell lymphoma","Mantle cell lymphoma"],"year":["2018"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Acute lymphoblastic leukaemia","href":"/cancers/all-leukemia/","tip":"Acute lymphoblastic leukaemia is the childhood cancer success story, and was the first disease treated with CAR-T and with a T-cell engager."},{"label":"Multiple myeloma","href":"/cancers/multiple-myeloma/","tip":"Multiple myeloma is a plasma-cell cancer with more new drug classes than any other: proteasome inhibitors, IMiDs, CD38 antibodies, BCMA CAR-T, bispecifics, and an ADC."},{"label":"Chronic lymphocytic leukaemia","href":"/cancers/cll/","tip":"A slow leukaemia that no longer needs chemotherapy: BTK inhibitors and venetoclax control it for years, often in fixed-duration courses."},{"label":"Diffuse large B-cell lymphoma","href":"/cancers/dlbcl/","tip":"Diffuse large B-cell lymphoma (DLBCL) is an aggressive but curable lymphoma. CAR-T cures about 40% of relapsed patients, and off-the-shelf bispecifics are now approved."}],"year":{"facet":"year","value":"2018"},"tags":[]},"sortKeys":{"year":2018}},{"id":"cobas-egfr-mutation-test","name":"cobas EGFR Mutation Test v2","tldr":"The lung cancer gene test that became the first blood-based companion diagnostic the FDA ever approved.","route":"/drugs/cobas-egfr-mutation-test/","status":"approved","kind":"drug","molecule":"cobas-egfr-mutation-test","modality":"Real-time PCR companion diagnostic test (tissue and plasma)","sub":"cobas EGFR Mutation Test","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":["2013"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"year":{"facet":"year","value":"2013"},"tags":[]},"sortKeys":{"year":2013}},{"id":"cologuard","name":"Cologuard","tldr":"A home stool test done every three years that looks for cancer DNA and hidden blood; a positive result means you need a colonoscopy.","route":"/drugs/cologuard/","status":"approved","kind":"drug","molecule":"cologuard","modality":"Multitarget stool DNA colorectal cancer screening test","sub":"Cologuard","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer"],"year":["2014"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely; chemotherapy still carries most metastatic disease, now with antibodies and targeted combinations chosen by RAS, BRAF, mismatch repair and which side of the bowel the tumour started on."}],"year":{"facet":"year","value":"2014"},"tags":[]},"sortKeys":{"year":2014}},{"id":"cologuard-plus","name":"Cologuard Plus","tldr":"The updated Cologuard, approved in 2024, which keeps the high cancer detection rate while causing fewer false alarms.","route":"/drugs/cologuard-plus/","status":"approved","kind":"drug","molecule":"cologuard-plus","modality":"Next-generation multitarget stool DNA colorectal cancer screening test","sub":"Cologuard Plus","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely; chemotherapy still carries most metastatic disease, now with antibodies and targeted combinations chosen by RAS, BRAF, mismatch repair and which side of the bowel the tumour started on."}],"year":{"facet":"year","value":"2024"},"tags":[]},"sortKeys":{"year":2024}},{"id":"cxbladder","name":"Cxbladder","tldr":"A urine test that can rule out bladder cancer in people with blood in their urine, so fewer need a camera examination of the bladder.","route":"/drugs/cxbladder/","status":"established","kind":"drug","molecule":"cxbladder","modality":"Urine mRNA biomarker test (bladder cancer detection and surveillance)","sub":"Cxbladder Detect / Triage / Monitor","facets":{"kind":["Treatment"],"cancers":["Bladder & urothelial cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"tags":[]},"sortKeys":{"year":0}},{"id":"dxcover-cancer-liquid-biopsy","name":"Dxcover Cancer Liquid Biopsy","tldr":"A Glasgow company's blood test that shines infrared light through serum to look for cancer; it is sold in the UK for brain tumours, and the multi-cancer version is still in study.","route":"/drugs/dxcover-cancer-liquid-biopsy/","status":"emerging","kind":"drug","molecule":"dxcover-cancer-liquid-biopsy","modality":"Multi-cancer blood test (infrared spectroscopy of serum)","sub":"Dxcover","facets":{"kind":["Treatment"],"cancers":["Glioma & glioblastoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Glioma & glioblastoma","href":"/cancers/glioblastoma/","tip":"Gliomas are now diagnosed by molecular class, and three classes got their first targeted drugs in 2024-25 (vorasidenib for IDH-mutant glioma, tovorafenib for BRAF-altered paediatric glioma, dordaviprone for H3 K27M). Glioblastoma is the hardest to treat: surgery, radiotherapy with temozolomide and tumour treating fields are its backbone, with CAR-T into the brain and focused ultrasound in trials."}],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"gagome-mced-test","name":"Elypta GAGome multi-cancer test","tldr":"A test in development from Elypta in Sweden that reads sugar molecules in urine and blood rather than DNA, aiming to flag many cancers including some that DNA tests find hard to see.","route":"/drugs/gagome-mced-test/","status":"emerging","kind":"drug","molecule":"gagome-mced-test","modality":"Multi-cancer early detection test in development (urine and plasma glycosaminoglycans)","sub":"GAGome","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"endopredict","name":"EndoPredict","tldr":"A 12-gene test that combines gene activity with tumour size and lymph nodes to say whether hormone therapy alone is enough, and whether to continue it beyond five years.","route":"/drugs/endopredict/","status":"established","kind":"drug","molecule":"endopredict","modality":"Gene-expression prognostic assay (12-gene EPclin score)","sub":"EndoPredict","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"tags":[]},"sortKeys":{"year":0}},{"id":"epipangi-dx","name":"EpiPanGI Dx","tldr":"A research blood test that looks for six digestive-system cancers at once and predicts which organ the signal comes from.","route":"/drugs/epipangi-dx/","status":"emerging","kind":"drug","molecule":"epipangi-dx","modality":"Gastrointestinal multi-cancer blood test, academic research assay (cell-free DNA methylation)","sub":"EpiPanGI Dx","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer","Hepatocellular carcinoma","Gastric & gastro-oesophageal junction cancer","Oesophageal cancer","Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely; chemotherapy still carries most metastatic disease, now with antibodies and targeted combinations chosen by RAS, BRAF, mismatch repair and which side of the bowel the tumour started on."},{"label":"Hepatocellular carcinoma","href":"/cancers/hcc/","tip":"Liver cancer almost always grows in a liver already damaged by hepatitis, alcohol or fatty liver disease. It is one of the most preventable cancers, and since 2020 immunotherapy combinations have roughly doubled how long people with advanced disease live."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."}],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"fludeoxyglucose-f18","name":"Fludeoxyglucose F-18 (FDG)","tldr":"The radioactive sugar used in almost every cancer PET scan, approved in the 1990s and made fresh each day by regional cyclotrons.","route":"/drugs/fludeoxyglucose-f18/","status":"approved","kind":"drug","molecule":"fludeoxyglucose-f18","modality":"PET imaging agent (glucose analogue)","sub":"FDG (multiple manufacturers)","facets":{"kind":["Treatment"],"cancers":[],"year":["1994"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"year":{"facet":"year","value":"1994"},"tags":[]},"sortKeys":{"year":1994}},{"id":"galleri","name":"Galleri","tldr":"GRAIL's blood test that looks for a signal from more than 50 cancers at once; an FDA advisory panel voted in its favour in September 2026, but in the NHS-Galleri randomised trial three yearly tests did not reduce the number of cancers found at a late stage.","route":"/drugs/galleri/","status":"phase-3","kind":"drug","molecule":"galleri","modality":"Multi-cancer early detection blood test","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"guardant-reveal","name":"Guardant Reveal","tldr":"A blood test for leftover cancer after surgery that needs no tumour sample, so results come faster than tumour-informed tests.","route":"/drugs/guardant-reveal/","status":"established","kind":"drug","molecule":"guardant-reveal","modality":"Tumour-naive ctDNA minimal residual disease test (methylation and genomic)","sub":"Guardant Reveal","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer","HR-positive / HER2-negative breast cancer","Non-small-cell lung cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely; chemotherapy still carries most metastatic disease, now with antibodies and targeted combinations chosen by RAS, BRAF, mismatch repair and which side of the bowel the tumour started on."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"tags":[]},"sortKeys":{"year":0}},{"id":"guardant360-cdx","name":"Guardant360 CDx","tldr":"A blood test that reads a tumour's mutations without a tissue biopsy and is the FDA-approved gateway to several targeted drugs.","route":"/drugs/guardant360-cdx/","status":"approved","kind":"drug","molecule":"guardant360-cdx","modality":"Liquid biopsy companion diagnostic test (NGS, cfDNA)","sub":"Guardant360 CDx","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","HR-positive / HER2-negative breast cancer","Pancreatic ductal adenocarcinoma","Colorectal cancer"],"year":["2020"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely; chemotherapy still carries most metastatic disease, now with antibodies and targeted combinations chosen by RAS, BRAF, mismatch repair and which side of the bowel the tumour started on."}],"year":{"facet":"year","value":"2020"},"tags":[]},"sortKeys":{"year":2020}},{"id":"her2-testing-assays","name":"HER2 IHC and ISH companion assays (HercepTest, PATHWAY 4B5, HER2 Dual ISH)","tldr":"The tests that grade a breast or stomach cancer's HER2 level, from the original trastuzumab test in 1998 to the new 'HER2-low' and 'ultralow' cut-offs.","route":"/drugs/her2-testing-assays/","status":"approved","kind":"drug","molecule":"her2-testing-assays","modality":"HER2 immunohistochemistry and in situ hybridisation companion diagnostic assays","sub":"HercepTest / PATHWAY anti-HER2 (4B5) / INFORM HER2 Dual ISH","facets":{"kind":["Treatment"],"cancers":["HER2-positive breast cancer","HR-positive / HER2-negative breast cancer","Gastric & gastro-oesophageal junction cancer","Triple-negative breast cancer"],"year":["1998"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"year":{"facet":"year","value":"1998"},"tags":[]},"sortKeys":{"year":1998}},{"id":"illuccix","name":"Illuccix (kit for Ga-68 gozetotide)","tldr":"Telix's ready-to-label kit that lets any nuclear medicine department make the gallium PSMA scan for prostate cancer.","route":"/drugs/illuccix/","status":"approved","kind":"drug","molecule":"illuccix","modality":"PET imaging agent kit (PSMA, gallium-68)","sub":"Illuccix / Gozellix","facets":{"kind":["Treatment"],"cancers":["Prostate cancer"],"year":["2021"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"year":{"facet":"year","value":"2021"},"tags":[]},"sortKeys":{"year":2021}},{"id":"locametz","name":"Locametz (kit for Ga-68 gozetotide)","tldr":"Novartis' gallium PSMA scan kit, approved the same day as Pluvicto as the test that qualifies men for that radioactive drug.","route":"/drugs/locametz/","status":"approved","kind":"drug","molecule":"locametz","modality":"PET imaging agent kit (PSMA, gallium-68)","sub":"Locametz","facets":{"kind":["Treatment"],"cancers":["Prostate cancer"],"year":["2022"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"year":{"facet":"year","value":"2022"},"tags":[]},"sortKeys":{"year":2022}},{"id":"lunit-insight-mmg","name":"Lunit INSIGHT MMG","tldr":"A Korean AI mammography reader used in screening programmes in Sweden and Australia and cleared in the US and Europe.","route":"/drugs/lunit-insight-mmg/","status":"approved","kind":"drug","molecule":"lunit-insight-mmg","modality":"AI mammography detection software","sub":"Lunit INSIGHT MMG","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer","Triple-negative breast cancer"],"year":["2019"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"year":{"facet":"year","value":"2019"},"tags":[]},"sortKeys":{"year":2019}},{"id":"caris-mi-cancer-seek","name":"MI Cancer Seek","tldr":"The first FDA-approved test that sequences all of a tumour's genes and gene activity at once, used to match patients to several targeted drugs.","route":"/drugs/caris-mi-cancer-seek/","status":"approved","kind":"drug","molecule":"caris-mi-cancer-seek","modality":"Whole-exome and whole-transcriptome companion diagnostic test","sub":"MI Cancer Seek","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer","Non-small-cell lung cancer","Melanoma","HR-positive / HER2-negative breast cancer","Pancreatic ductal adenocarcinoma"],"year":["2024"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely; chemotherapy still carries most metastatic disease, now with antibodies and targeted combinations chosen by RAS, BRAF, mismatch repair and which side of the bowel the tumour started on."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Melanoma","href":"/cancers/melanoma/","tip":"The skin cancer that proved immunotherapy works: half of advanced patients now live 10 years. Also the first with an approved TIL therapy, an oncolytic virus, and a positive phase 3 personalised vaccine."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"year":{"facet":"year","value":"2024"},"tags":[]},"sortKeys":{"year":2024}},{"id":"kheiron-mia","name":"Mia (Mammography Intelligent Assessment)","tldr":"A London-built breast screening AI trialled across NHS sites as a second reader, now folded into RadNet's DeepHealth after a 2024 acquisition.","route":"/drugs/kheiron-mia/","status":"established","kind":"drug","molecule":"kheiron-mia","modality":"AI mammography detection software (independent or second reader)","sub":"Mia","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer","Triple-negative breast cancer"],"year":["2019"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"year":{"facet":"year","value":"2019"},"tags":[]},"sortKeys":{"year":2019}},{"id":"mychoice-cdx","name":"myChoice CDx","tldr":"A tumour test that measures DNA-repair scarring so that women with ovarian cancer beyond BRCA carriers can benefit from PARP inhibitors.","route":"/drugs/mychoice-cdx/","status":"approved","kind":"drug","molecule":"mychoice-cdx","modality":"Tumour HRD genomic instability companion diagnostic test","sub":"myChoice CDx","facets":{"kind":["Treatment"],"cancers":["Ovarian cancer","Triple-negative breast cancer"],"year":["2019"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Ovarian cancer","href":"/cancers/ovarian/","tip":"Usually found late. PARP inhibitors transformed maintenance therapy, and ADCs against folate receptor and CDH6 are arriving for platinum-resistant disease."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"year":{"facet":"year","value":"2019"},"tags":[]},"sortKeys":{"year":2019}},{"id":"n-nose","name":"N-NOSE","tldr":"A Japanese urine test that uses the sense of smell of tiny worms; it is sold directly to the public in Japan, does not say which cancer, and in a real-world analysis about 2 in 100 people with a positive result were found to have cancer (about 12 in 100 after allowing for cancers the follow-up scan can miss).","route":"/drugs/n-nose/","status":"emerging","kind":"drug","molecule":"n-nose","modality":"Cancer risk urine test (nematode smell response)","sub":"N-NOSE","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"novelna-protein-test","name":"Novelna sex-specific protein test","tldr":"An experimental blood test that reads a handful of proteins, with different panels for men and women, to find many early cancers; so far it has been tried only on a few hundred stored samples.","route":"/drugs/novelna-protein-test/","status":"emerging","kind":"drug","molecule":"novelna-protein-test","modality":"Multi-cancer blood test in development (plasma proteins, proximity extension assay)","sub":"Novelna","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"nu-q-cancer","name":"Nu.Q Cancer","tldr":"VolitionRx's blood test that measures DNA packaging released by dying cells; a version is sold for dogs, and the human multi-cancer test is at preprint stage.","route":"/drugs/nu-q-cancer/","status":"emerging","kind":"drug","molecule":"nu-q-cancer","modality":"Multi-cancer blood test in development (circulating nucleosome immunoassay)","sub":"Nu.Q","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"oncodetect","name":"Oncodetect","tldr":"Exact Sciences' entry into the leftover-cancer blood test market, launched in 2025 for bowel cancer follow-up.","route":"/drugs/oncodetect/","status":"emerging","kind":"drug","molecule":"oncodetect","modality":"Tumour-informed ctDNA minimal residual disease test","sub":"Oncodetect","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely; chemotherapy still carries most metastatic disease, now with antibodies and targeted combinations chosen by RAS, BRAF, mismatch repair and which side of the bowel the tumour started on."}],"tags":[]},"sortKeys":{"year":0}},{"id":"oncomine-dx-target-test","name":"Oncomine Dx Target Test","tldr":"The first FDA-approved gene panel that could match one biopsy to several different lung cancer drugs at once.","route":"/drugs/oncomine-dx-target-test/","status":"approved","kind":"drug","molecule":"oncomine-dx-target-test","modality":"Tissue NGS companion diagnostic test (multi-gene panel)","sub":"Oncomine Dx Target Test","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Biliary tract cancer"],"year":["2017"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Biliary tract cancer","href":"/cancers/cholangiocarcinoma/","tip":"Cholangiocarcinoma is cancer of the bile ducts or gallbladder. It is rare and often found late, but it turned out to carry more targetable mutations than almost any other gastrointestinal cancer, and immunotherapy now adds to chemotherapy from the first treatment."}],"year":{"facet":"year","value":"2017"},"tags":[]},"sortKeys":{"year":2017}},{"id":"oncoseek","name":"OncoSeek","tldr":"SeekIn's low-cost protein blood test for 14 cancers, designed for countries that cannot afford DNA sequencing; it finds about six in ten cancers but flags about one in twelve people without cancer.","route":"/drugs/oncoseek/","status":"emerging","kind":"drug","molecule":"oncoseek","modality":"Multi-cancer blood test (seven protein tumour markers with artificial intelligence)","sub":"OncoSeek","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"oncotype-dx-gps","name":"Oncotype DX Genomic Prostate Score","tldr":"A 17-gene biopsy test that helps men with newly diagnosed low-risk prostate cancer decide whether to watch or treat.","route":"/drugs/oncotype-dx-gps/","status":"established","kind":"drug","molecule":"oncotype-dx-gps","modality":"Gene-expression prognostic assay (17-gene Genomic Prostate Score)","sub":"Oncotype DX GPS","facets":{"kind":["Treatment"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"onetest","name":"OneTest for Cancer","tldr":"A low-cost blood test from 20/20 BioLabs that measures a panel of protein tumour markers and is sold in the United States as a laboratory test without FDA review.","route":"/drugs/onetest/","status":"emerging","kind":"drug","molecule":"onetest","modality":"Multi-cancer blood test (panel of serum tumour-associated proteins)","sub":"OneTest","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"optellum-virtual-nodule-clinic","name":"Optellum Virtual Nodule Clinic","tldr":"The first AI cleared to estimate how likely a lung nodule on a CT scan is to be cancer, helping doctors decide who needs a biopsy and who can wait.","route":"/drugs/optellum-virtual-nodule-clinic/","status":"approved","kind":"drug","molecule":"optellum-virtual-nodule-clinic","modality":"AI lung nodule malignancy prediction software (CT)","sub":"Virtual Nodule Clinic","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":["2020"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"year":{"facet":"year","value":"2020"},"tags":[]},"sortKeys":{"year":2020}},{"id":"overc-mcdbt","name":"OverC Multi-Cancer Detection Blood Test","tldr":"Burning Rock's methylation blood test from China for five or six cancers, with Breakthrough designations from the US and Chinese regulators but no approval yet.","route":"/drugs/overc-mcdbt/","status":"emerging","kind":"drug","molecule":"overc-mcdbt","modality":"Multi-cancer early detection blood test (cell-free DNA methylation, ELSA-seq)","sub":"OverC","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"paige-prostate","name":"Paige Prostate Detect","tldr":"The first AI for reading biopsy slides authorised by the FDA, which points pathologists to prostate cancer they might otherwise miss.","route":"/drugs/paige-prostate/","status":"approved","kind":"drug","molecule":"paige-prostate","modality":"AI digital pathology detection software (prostate biopsy)","sub":"Paige Prostate","facets":{"kind":["Treatment"],"cancers":["Prostate cancer"],"year":["2019"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"year":{"facet":"year","value":"2019"},"tags":[{"label":"precision","href":"/tagged/precision/","tip":"Every record tagged precision."}]},"sortKeys":{"year":2019}},{"id":"panseer","name":"PanSeer","tldr":"Singlera's methylation blood test, tested on stored samples from a Chinese cohort, that reported finding cancers up to four years before they were diagnosed; it has not been confirmed in a prospective study.","route":"/drugs/panseer/","status":"emerging","kind":"drug","molecule":"panseer","modality":"Multi-cancer blood test (circulating tumour DNA methylation), research assay","sub":"PanSeer","facets":{"kind":["Treatment"],"cancers":["Gastric & gastro-oesophageal junction cancer","Oesophageal cancer","Colorectal cancer","Lung cancer","Hepatocellular carcinoma"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Oesophageal cancer","href":"/cancers/esophageal/","tip":"Oesophageal cancer is really two diseases sharing one organ: squamous cell carcinoma, which dominates in Asia, and adenocarcinoma, which dominates in the West and is treated like gastric cancer. Immunotherapy is now standard, and the bispecific ADC iza-bren posted a positive phase 3 in the squamous type in 2026."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely; chemotherapy still carries most metastatic disease, now with antibodies and targeted combinations chosen by RAS, BRAF, mismatch repair and which side of the bowel the tumour started on."},{"label":"Lung cancer","href":"/cancers/lung-cancer/","tip":"Lung cancer splits into non-small-cell disease, about 85 percent of it, and small-cell disease, which was 6.6 percent of English cases in 2024 and 9.1 percent of Welsh ones (National Lung Cancer Audit, State of the Nation 2026); the two behave and are treated very differently. Screening, staging and the things both types share are common ground; the rest belongs to each subtype."}],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"pantum-detect","name":"PanTum Detect","tldr":"A German blood test sold through a private health insurance add-on, which claims to signal cancer of any type; its published evidence is small studies and case reports.","route":"/drugs/pantum-detect/","status":"emerging","kind":"drug","molecule":"pantum-detect","modality":"Cancer blood test (Apo10 and TKTL1 epitopes in monocytes, flow cytometry)","sub":"PanTum Detect","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"dako-pd-l1-22c3-pharmdx","name":"PD-L1 IHC 22C3 pharmDx","tldr":"The 22C3 pharmDx assay is the PD-L1 stain tied to pembrolizumab since 2015 and the source of the combined positive score (CPS). The cut-off differs by cancer: 1% of tumour cells in lung cancer, CPS 1 in gastric, cervical and head and neck cancer, CPS 10 in oesophageal and triple-negative breast cancer, so one stain is read differently per disease.","route":"/drugs/dako-pd-l1-22c3-pharmdx/","status":"approved","kind":"drug","molecule":"dako-pd-l1-22c3-pharmdx","modality":"PD-L1 immunohistochemistry companion diagnostic assay","sub":"PD-L1 IHC 22C3 pharmDx","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer","Gastric & gastro-oesophageal junction cancer","Cervical cancer","Head and neck squamous cell carcinoma","Oesophageal cancer","Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":["2015"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Gastric & gastro-oesophageal junction cancer","href":"/cancers/gastric/","tip":"A cancer with three new targets in five years: Claudin 18.2, FGFR2b, and HER2 with new ADCs, plus immunotherapy in first line."},{"label":"Cervical cancer","href":"/cancers/cervical/","tip":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival."},{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."}],"year":{"facet":"year","value":"2015"},"tags":[]},"sortKeys":{"year":2015}},{"id":"icad-profound-ai","name":"ProFound AI (iCAD)","tldr":"The first AI cleared for 3D mammography in the US, now part of RadNet's imaging network.","route":"/drugs/icad-profound-ai/","status":"approved","kind":"drug","molecule":"icad-profound-ai","modality":"AI mammography and tomosynthesis detection software","sub":"ProFound Detection","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer","Triple-negative breast cancer"],"year":["2018"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"year":{"facet":"year","value":"2018"},"tags":[]},"sortKeys":{"year":2018}},{"id":"prolaris","name":"Prolaris","tldr":"A gene test on a prostate biopsy that estimates how aggressive the cancer is, to help decide between active surveillance and treatment.","route":"/drugs/prolaris/","status":"established","kind":"drug","molecule":"prolaris","modality":"Gene-expression prognostic assay (cell-cycle progression score, prostate)","sub":"Prolaris","facets":{"kind":["Treatment"],"cancers":["Prostate cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Prostate cancer","href":"/cancers/prostate/","tip":"Prostate cancer is the home of theranostics: PSMA PET finds it, PSMA radioligands treat it. Hormonal therapy remains the foundation, with PARP and AKT inhibitors added by genotype."}],"tags":[]},"sortKeys":{"year":0}},{"id":"prosigna","name":"Prosigna (PAM50)","tldr":"A 50-gene test run in local hospital laboratories that estimates the ten-year risk of a hormone-positive breast cancer coming back.","route":"/drugs/prosigna/","status":"approved","kind":"drug","molecule":"prosigna","modality":"Gene-expression prognostic assay (50-gene PAM50 risk of recurrence)","sub":"Prosigna","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer"],"year":["2012"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."}],"year":{"facet":"year","value":"2012"},"tags":[]},"sortKeys":{"year":2012}},{"id":"radar-mrd","name":"RaDaR","tldr":"NeoGenomics' personalised blood test for tiny amounts of leftover cancer, tracking up to 48 mutations from the patient's own tumour.","route":"/drugs/radar-mrd/","status":"established","kind":"drug","molecule":"radar-mrd","modality":"Tumour-informed ctDNA minimal residual disease test (up to 48 variants)","sub":"RaDaR","facets":{"kind":["Treatment"],"cancers":["Head and neck squamous cell carcinoma","Non-small-cell lung cancer","HR-positive / HER2-negative breast cancer","Triple-negative breast cancer"],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Head and neck squamous cell carcinoma","href":"/cancers/head-and-neck/","tip":"Cancers of the mouth and throat, increasingly caused by HPV. Immunotherapy is first line for advanced disease and now used before surgery."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"tags":[]},"sortKeys":{"year":0}},{"id":"resolution-ctdx-first","name":"Resolution ctDx FIRST","tldr":"A blood test approved with adagrasib to find the KRAS G12C mutation in lung cancer when a tissue biopsy is not possible.","route":"/drugs/resolution-ctdx-first/","status":"approved","kind":"drug","molecule":"resolution-ctdx-first","modality":"Liquid biopsy companion diagnostic test (NGS, cfDNA)","sub":"Resolution ctDx FIRST","facets":{"kind":["Treatment"],"cancers":["Non-small-cell lung cancer"],"year":["2022"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."}],"year":{"facet":"year","value":"2022"},"tags":[]},"sortKeys":{"year":2022}},{"id":"harbinger-resolve","name":"RESOLVE (Harbinger Health)","tldr":"Harbinger Health's blood test meant for the weeks between a doctor suspecting cancer and a diagnosis, pointing to where in the body a cancer may be; it is not offered as a screening test for well people.","route":"/drugs/harbinger-resolve/","status":"emerging","kind":"drug","molecule":"harbinger-resolve","modality":"Multi-cancer blood test for people with suspected cancer (cell-free DNA methylation)","sub":"RESOLVE","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"seekincare","name":"SeekInCare","tldr":"SeekIn's multi-omic blood test that adds DNA sequencing to its protein test; in published studies it found about six to seven in ten cancers and about four in ten at stage I.","route":"/drugs/seekincare/","status":"emerging","kind":"drug","molecule":"seekincare","modality":"Multi-cancer early detection blood test (shallow whole-genome cell-free DNA plus seven proteins)","sub":"SeekInCare","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"shield-mcd","name":"Shield MCD (Shield Multi-Cancer Detection)","tldr":"Guardant Health's blood test for ten cancers, offered in the United States as an add-on report to its bowel cancer blood test and chosen by the US National Cancer Institute for its first randomised study of such tests.","route":"/drugs/shield-mcd/","status":"emerging","kind":"drug","molecule":"shield-mcd","modality":"Multi-cancer early detection blood test (cell-free DNA methylation)","sub":"Shield MCD","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"simplescreen-crc","name":"SimpleScreen CRC","tldr":"The second FDA-approved blood test for bowel cancer screening, from Freenome, sold by Abbott from late 2026.","route":"/drugs/simplescreen-crc/","status":"approved","kind":"drug","molecule":"simplescreen-crc","modality":"Blood-based colorectal cancer screening test (cfDNA methylation and protein)","sub":"SimpleScreen","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer"],"year":["2026"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely; chemotherapy still carries most metastatic disease, now with antibodies and targeted combinations chosen by RAS, BRAF, mismatch repair and which side of the bowel the tumour started on."}],"year":{"facet":"year","value":"2026"},"tags":[]},"sortKeys":{"year":2026}},{"id":"spot-mas","name":"SPOT-MAS","tldr":"Gene Solutions' low-cost blood test from Vietnam; in 9,024 people without symptoms about one in two hundred tested positive and four in ten of those had cancer.","route":"/drugs/spot-mas/","status":"emerging","kind":"drug","molecule":"spot-mas","modality":"Multi-cancer early detection blood test (cell-free DNA methylation, fragment size, copy number)","sub":"SPOT-MAS","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"tempus-xt-cdx","name":"Tempus xT CDx","tldr":"Tempus's tumour-and-normal gene panel, FDA-approved in 2023 as a companion test for EGFR antibodies in bowel cancer.","route":"/drugs/tempus-xt-cdx/","status":"approved","kind":"drug","molecule":"tempus-xt-cdx","modality":"Tissue NGS companion diagnostic test (648 genes, tumour-normal)","sub":"xT CDx","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer","Pancreatic ductal adenocarcinoma"],"year":["2023"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely; chemotherapy still carries most metastatic disease, now with antibodies and targeted combinations chosen by RAS, BRAF, mismatch repair and which side of the bowel the tumour started on."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"year":{"facet":"year","value":"2023"},"tags":[]},"sortKeys":{"year":2023}},{"id":"therascreen-cdx","name":"therascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)","tldr":"A family of quick single-gene tests that decide who can have several bowel, lung, breast and bladder cancer drugs.","route":"/drugs/therascreen-cdx/","status":"approved","kind":"drug","molecule":"therascreen-cdx","modality":"Real-time PCR companion diagnostic test family","sub":"therascreen","facets":{"kind":["Treatment"],"cancers":["Colorectal cancer","Non-small-cell lung cancer","HR-positive / HER2-negative breast cancer","Bladder & urothelial cancer"],"year":["2012"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely; chemotherapy still carries most metastatic disease, now with antibodies and targeted combinations chosen by RAS, BRAF, mismatch repair and which side of the bowel the tumour started on."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"year":{"facet":"year","value":"2012"},"tags":[]},"sortKeys":{"year":2012}},{"id":"thromboseq","name":"thromboSeq (tumour-educated platelet RNA)","tldr":"An Amsterdam research test that reads RNA inside blood platelets and detected 18 cancer types in a laboratory study, though it often flagged people with other illnesses.","route":"/drugs/thromboseq/","status":"emerging","kind":"drug","molecule":"thromboseq","modality":"Multi-cancer blood test, academic research assay (platelet RNA sequencing)","sub":"thromboSeq","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"transpara","name":"Transpara","tldr":"The breast screening AI tested in Sweden's MASAI trial, where AI-supported reading found more cancers and nearly halved the radiologists' workload.","route":"/drugs/transpara/","status":"approved","kind":"drug","molecule":"transpara","modality":"AI mammography detection and decision-support software","sub":"Transpara","facets":{"kind":["Treatment"],"cancers":["HR-positive / HER2-negative breast cancer","HER2-positive breast cancer","Triple-negative breast cancer"],"year":["2017"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"HR-positive / HER2-negative breast cancer","href":"/cancers/breast-hr-positive/","tip":"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."},{"label":"HER2-positive breast cancer","href":"/cancers/breast-her2-positive/","tip":"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"year":{"facet":"year","value":"2017"},"tags":[]},"sortKeys":{"year":2017}},{"id":"trucheck-intelli","name":"Trucheck Intelli","tldr":"Datar Cancer Genetics' blood test that looks for clumps of tumour cells, sold privately in the UK; the developer's marketing figures go beyond what its own papers report.","route":"/drugs/trucheck-intelli/","status":"emerging","kind":"drug","molecule":"trucheck-intelli","modality":"Multi-cancer blood test (circulating tumour cell clusters, immunocytochemistry)","sub":"Trucheck","facets":{"kind":["Treatment"],"cancers":[],"year":[]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[],"tags":[{"label":"mced","href":"/tagged/mced/","tip":"Every record tagged mced."}]},"sortKeys":{"year":0}},{"id":"trusight-oncology-comprehensive","name":"TruSight Oncology Comprehensive","tldr":"A large gene panel hospitals can run themselves, approved by the FDA in 2024 as a companion diagnostic for the tumour-agnostic drug larotrectinib.","route":"/drugs/trusight-oncology-comprehensive/","status":"approved","kind":"drug","molecule":"trusight-oncology-comprehensive","modality":"Distributable tissue NGS companion diagnostic test (500+ genes, DNA and RNA)","sub":"TSO Comprehensive","facets":{"kind":["Treatment"],"cancers":["Pancreatic ductal adenocarcinoma","Colorectal cancer"],"year":["2022"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely; chemotherapy still carries most metastatic disease, now with antibodies and targeted combinations chosen by RAS, BRAF, mismatch repair and which side of the bowel the tumour started on."}],"year":{"facet":"year","value":"2022"},"tags":[]},"sortKeys":{"year":2022}},{"id":"urovysion","name":"UroVysion Bladder Cancer Kit","tldr":"A urine test that looks for chromosome changes in shed bladder cells, approved for people with blood in the urine and for follow-up after bladder cancer.","route":"/drugs/urovysion/","status":"approved","kind":"drug","molecule":"urovysion","modality":"Urine FISH cytogenetic test (bladder cancer)","sub":"UroVysion","facets":{"kind":["Treatment"],"cancers":["Bladder & urothelial cancer"],"year":["2001"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."}],"year":{"facet":"year","value":"2001"},"tags":[]},"sortKeys":{"year":2001}},{"id":"ventana-mmr-rxdx","name":"VENTANA MMR RxDx Panel","tldr":"A four-stain test that shows whether a womb cancer has lost its DNA spell-checker, which makes immunotherapy likely to work.","route":"/drugs/ventana-mmr-rxdx/","status":"approved","kind":"drug","molecule":"ventana-mmr-rxdx","modality":"Mismatch-repair immunohistochemistry companion diagnostic assay","sub":"VENTANA MMR RxDx","facets":{"kind":["Treatment"],"cancers":["Endometrial cancer","Colorectal cancer","Pancreatic ductal adenocarcinoma"],"year":["2021"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Endometrial cancer","href":"/cancers/endometrial/","tip":"The gynaecological cancer where immunotherapy has had the biggest impact, guided by molecular classification."},{"label":"Colorectal cancer","href":"/cancers/colorectal/","tip":"The cancer where screening works best and where immunotherapy can make some tumours disappear entirely; chemotherapy still carries most metastatic disease, now with antibodies and targeted combinations chosen by RAS, BRAF, mismatch repair and which side of the bowel the tumour started on."},{"label":"Pancreatic ductal adenocarcinoma","href":"/cancers/pancreatic/","tip":"Almost every pancreatic tumour carries a KRAS mutation, and for the first time drugs against it work: daraxonrasib nearly doubled survival in previously treated disease in 2026. Pancreatic cancer has been the hardest common cancer to treat once advanced; that is what is starting to change."}],"year":{"facet":"year","value":"2021"},"tags":[]},"sortKeys":{"year":2021}},{"id":"ventana-pd-l1-sp142","name":"VENTANA PD-L1 (SP142) Assay","tldr":"The PD-L1 stain that decides who can have atezolizumab, scored on immune cells rather than tumour cells in breast cancer.","route":"/drugs/ventana-pd-l1-sp142/","status":"approved","kind":"drug","molecule":"ventana-pd-l1-sp142","modality":"PD-L1 immunohistochemistry companion diagnostic assay","sub":"VENTANA PD-L1 (SP142)","facets":{"kind":["Treatment"],"cancers":["Bladder & urothelial cancer","Non-small-cell lung cancer","Triple-negative breast cancer","Metastatic triple-negative breast cancer"],"year":["2016"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."},{"label":"Metastatic triple-negative breast cancer","href":"/cancers/tnbc-metastatic/","tip":"The treatment of triple-negative breast cancer that has spread has been transformed since 2020, though it is not yet curable. By PD-L1 score, first treatment is pembrolizumab with chemotherapy or with sacituzumab govitecan, or datopotamab deruxtecan or sacituzumab govitecan alone; BRCA carriers can take a PARP inhibitor tablet; and trastuzumab deruxtecan reaches the third of tumours with low HER2."}],"year":{"facet":"year","value":"2016"},"tags":[]},"sortKeys":{"year":2016}},{"id":"ventana-pd-l1-sp263","name":"VENTANA PD-L1 (SP263) Assay","tldr":"The VENTANA SP263 assay is an immunohistochemistry stain that measures PD-L1 on tumour cells. Approved in 2017 alongside durvalumab in bladder cancer, it became the companion test in 2021 for adjuvant atezolizumab in resected lung cancer with PD-L1 on at least 1% of tumour cells, and it agrees closely with 22C3, so laboratories often validate it as a single platform.","route":"/drugs/ventana-pd-l1-sp263/","status":"approved","kind":"drug","molecule":"ventana-pd-l1-sp263","modality":"PD-L1 immunohistochemistry companion diagnostic assay","sub":"VENTANA PD-L1 (SP263)","facets":{"kind":["Treatment"],"cancers":["Bladder & urothelial cancer","Non-small-cell lung cancer","Triple-negative breast cancer"],"year":["2017"]},"cols":{"kind":{"facet":"kind","value":"Treatment","tip":"Approved and pipeline products, with what they hit and who makes them."},"cancers":[{"label":"Bladder & urothelial cancer","href":"/cancers/urothelial/","tip":"Bladder cancer went from 40 years of cisplatin to an ADC-immunotherapy combination that nearly doubled survival, and in 2026 the first blood-test-guided drug approval."},{"label":"Non-small-cell lung cancer","href":"/cancers/nsclc/","tip":"Non-small-cell lung cancer is the proving ground for precision medicine: a dozen targetable mutations each with a matched pill, immunotherapy for the rest, and ADCs and bispecifics arriving now. Because most cases are still found late, low-dose CT screening is the other half of the story."},{"label":"Triple-negative breast cancer","href":"/cancers/tnbc/","tip":"A breast cancer that lacks the three receptors (oestrogen, progesterone, HER2) that other breast cancers can be treated through. It was the hardest subtype for decades; since 2020 immunotherapy and ADCs have changed that."}],"year":{"facet":"year","value":"2017"},"tags":[]},"sortKeys":{"year":2017}}]